-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Ultragenyx Pharmaceutical, Lowers Price Target to $35

Benzinga·08/04/2026 11:52:10
语音播报
Guggenheim analyst Debjit Chattopadhyay maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price target from $43 to $35.